ALYKOMED GLOBAL SOLUTIONS LLC

Excellence in Lifesciences and Biopharma

Alykomed Global Solutions LLC (AGSL)

​

​Overview

Founded in 2018 and headquartered in New York and Tokyo, Alykomed Global Solutions LLC (AGSL) is a boutique advisory and investment firm specializing in early regulatory strategy, pre-IND/IND consultation, and strategic business development solutions for innovative biopharmaceutical, life sciences, and medical device companies worldwide.

AGSL supports emerging and established innovators seeking to disrupt and improve patient care through cutting-edge technologies across therapeutics, diagnostics, AI, and digital health.

​

Our Three Core Divisions

1. Partnering & Business Development Support

AGSL delivers personalized, end-to-end strategic corporate solutions for innovative biopharma and life sciences companies. Our mission is to support visionary teams developing technologies that transform healthcare.

​

We work closely with each client to design and execute optimized strategies aligned with their scientific, regulatory, and commercial objectives. Our approach integrates:

• Deep scientific expertise

• Proven corporate and business development leadership

• Global market awareness

• Creative, opportunity-driven strategy

​​​

AGSL is a trusted partner to both:

• Innovators seeking development, capital, and strategic partners

• Investors and global biopharma companies seeking high-value, differentiated opportunities

​​

Our client portfolio spans early-stage startups to established public companies. Engagements include:

• Global business development and partnering

• Capital and investment support

• Scientific and strategic diligence

​​

We operate through a worldwide professional network with strong experience across North America, Europe, and Asia—particularly the United States, Japan, and South Korea.

​

​

2. Strategic Regulatory Support

AGSL develops and executes integrated regulatory roadmaps across major global agencies including FDA, EMA, and ISO.

We combine scientific insight with a detailed understanding of regulatory expectations to:

• Reduce development risk

• Accelerate regulatory timelines

• Increase asset and company valuation

​​

​Our services include:

• Early regulatory strategy (Pre-IND / IND)

• Global regulatory pathway planning

• Regulatory positioning for partnering and financing

​​

Beyond regulatory strategy, AGSL provides:

• Scientific and regulatory due diligence

• Partnering support aligned with regulatory milestones

• Integrated development risk mitigation

​​

By aligning regulatory strategy with commercial goals, AGSL helps clients achieve faster approvals and stronger strategic outcomes.

​

3. AGSL Seed Investment Arm

In 2021, AGSL launched its own seed investment arm, extending our commitment to promising innovators through direct financial participation.

​

AGSL selectively invests in client and partner companies whose technologies demonstrate:

• Strong scientific rationale

• Clear regulatory pathways

• High-value partnering or commercialization potential

​​

In selected cases, AGSL has:

• Invested directly in client companies

• Acquired equity positions as part of strategic engagements

​​

This model aligns AGSL’s success with that of our clients, reinforcing long-term partnership and shared value creation.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Core Focus

Early Regulatory Strategy (Pre-IND / IND)

We provide highly experienced guidance to secure favorable regulatory pathways while minimizing time-to-market and avoiding costly setbacks.

​

Strategic Growth & Capital Sourcing

We position clients for:

• Financing

• Strategic partnerships

• In-licensing and out-licensing

When appropriate, we provide direct access to senior decision-makers across the global biopharma and investment ecosystem.

​

Global Access with Strength in the Far East

With a network spanning North America, Europe, Asia, and the Middle East, AGSL maintains a specialized strategic presence in Japan, including a partnering collaboration with the Japan Agency for Medical Research and Development (AMED).

Value Proposition

• Boutique, senior-level attention

• Integrated scientific, regulatory, and commercial strategy

• Global reach with local expertise

• Proven ability to de-risk development and accelerate growth

​​

​

AGSL CURRENT CLIENT PORTFOLIO (as of 02-2026)

Our AGSL portfolio includes 22 active clients across:

• Therapeutics (preclinical through Phase II)

• Medical devices

• Digital health

• ​

We routinely engage with global biopharma partnering executives and investors seeking high-value innovative platforms that align with their strategic priorities.

​

Our Mission

To support innovative companies developing transformative healthcare technologies by integrating regulatory excellence, strategic growth planning, and capital access—driving long-term success and improved patient outcomes.

​

Contact us to learn more.

​

Alykomed Global Solutions is a strong supporter of the International Cancer Advocacy Network (www.askICAN.org), a globally recognized 501(c)(3) tax-exempt charitable organization that provides personalized across the board support for late stage cancer patients, and has assisted over 13,000 individual patients and their families since 1996.